Company plans to advance VG-3927 into a Phase 2 trial in the third quarter of 2025; Selects 25mg QD oral as a dose that fully engages desired pharmacology - WATERTOWN, Mass., Jan. 23, 2025 (GLOBE ...

NEW YORK, NY / ACCESS Newswire / March 29, 2025 / If you suffered a loss on your Venture Global, Inc. (NYSE:VG) investment and want to learn about a potential recovery under the federal securities ...